Gerresheimer Ag · XETR:GXI
Gerresheimer — Investor Day (October 2008)
11 slides from Gerresheimer's investor day presentation, Oct 23, 2008
Slide 1: Gerresheimer Capital Markets Day: Update on financial performance
Gerresheimer Capital Markets Day: Update on financial performance October 23+24, 2008 Hans-Jürgen Wiecha, CFO 0
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Excellent group sales and earnings development YTD
Excellent group sales and earnings development YTD Net sales and adjusted EBITDA EUR m Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q3 2008: 18.8% rate: 15.8% Q1-Q3 2007: 17.8% Net sales growth driven by high +12.3% demand for pharma and 697.4 783.4 cosmetic products Margin expansion
Slide 4: Tubular Glass: Favorable sales trends in RTF syringes and vials drive growth
Tubular Glass: Favorable sales trends in RTF syringes and vials drive growth Net sales and adjusted EBITDA EUR m Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q3 2008: 24.5% rate: 16.5% Q1-Q3 2007: 24.0% Sales of RTF syringes up 48.9% compared with Q1-Q3 2007 +11.2% 221.3 199.0 Contin
Slide 5: Plastic Systems: Margin increase reflects operational progress
Plastic Systems: Margin increase reflects operational progress Net sales and adjusted EBITDA EUR m Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q3 2008: 18.4% rate: 17.8% Q1-Q3 2007: 17.5% Strong growth driven by +18.3% favorable development in 258.6 Inhalation and Diagnostics 218.6
Slide 6: Moulded Glass: Outperformance of market growth
Moulded Glass: Outperformance of market growth Net sales and adjusted EBITDA EUR m Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q3 2008: 21.1% rate: 8.4% Q1-Q3 2007: 19.3% Pharma bottles in US and Europe +5.4% and cosmetic products in 234.3 246.9 European and emerging markets drove s
Slide 7: Life Science Research: Margin uplift of 230 basis points
Life Science Research: Margin uplift of 230 basis points Net sales and adjusted EBITDA EUR m Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q3 2008: 11.9% rate: +61.6% Q1-Q3 2007: 9.6% High growth in sales and adjusted EBITDA triggered by Kimble Chase JV +41.1% Ongoing portfolio optimi
Slide 8: Solid capital structure
Solid capital structure Q1-Q3 as of Q1-Q3 as of FY 2007 as of EUR m Aug 31, 2008 Aug 31, 2007 Nov 30, 2007 Equity 480.2 491.5 -2.3% 499.9 Equity ratio in % 33.6 34.2 34.8 Net working capital1 205.9 187.0 +10.1% 179.8 in % of LTM net sales 19.7 21.6 18.8 Net financial debt2 437.8 414.3 +5.7% 390.6 Ad
Slide 9: Constant decrease of leverage
Constant decrease of leverage EUR m Acquistion of EDP + Allplas 458.1 456.2 437.8 414.3 390.6 2.4 Adjusted EBITDA 2.4 leverage 2.3 Net debt 2.2 2.1 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 8
Slide 10: Secured long-term financing structure; liquidity reserves through EUR 175m committed revolver
Secured long-term financing structure; liquidity reserves through EUR 175m committed revolver Debt/cash positions in EUR m1 Interest rate Due by Net financial debt 437.8 Bond 126.0 7.9%; Fixed coupon 2015 Long-term 5.7%; Hedged 100% 2012 / 2013 bank debt 232.0 until Sep 2010 55bps over Euribor/Libor
Slide 11: Further investments in profitable growth projects
Further investments in profitable growth projects Capex by segment in EUR m Major investments: 54.1 Life Science Research 1.0 3rd production line Moulded Glass 12.2 for RTF syringes New facility for pen production in the Czech Republic Plastic Systems 21.3 Expansion of inhaler production facilities